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Novel Protein-Based Pneumococcal Vaccines Administered with the
Th1-Promoting Adjuvant IC31 Induce Protective Immunity against
Pneumococcal Disease in Neonatal Mice
Thorunn Asta Olafsdottir,a,b Karen Lingnau,c Eszter Nagy,c* and Ingileif Jonsdottira,b,d
Landspitali, The National University Hospital of Iceland, Department of Immunology, Reykjavik, Icelanda; University of Iceland Faculty of Medicine, Reykjavik, Icelandb;
Intercell AG, Vienna, Austriac; and deCODE Genetics, Reykjavik, Icelandd
Streptococcus pneumoniae is responsible formany vaccine-preventable deaths, annually causing around 1million deaths in children
younger than 5 years of age. A new generation of pneumococcal vaccines based on conserved proteins is being developed.We evaluated
the immunogenicities and protective efficacies of four pneumococcal protein vaccine candidates, PcsB, StkP, PsaA, andPspA, in a neo-
natalmousemodel.Micewere immunized three times and challenged intranasallywith virulent pneumococci. All four proteinswere
immunogenic in neonatalmice, and antibody (Ab) responseswere significantly enhanced by the novel adjuvant IC31,which consists of
an antibacterial peptide (KLKL5KLK) and a synthetic oligodeoxynucleotide,ODN1a, that signals throughToll-like receptor 9 (TLR9).
Two single proteins, StkP andPspA, combinedwith IC31 significantly reduced pneumococcal bacteremia but hadno effects on lung
infection. Three proteins, PcsB, StkP, andPsaA,were evaluatedwith alumor IC31. IC31 enhancedAb responses and avidity to all three
proteins, whereas alumenhancedAb responses and avidity to StkP andPsaAonly.Mice receiving the trivalent protein formulation
with IC31 had significantly reduced bacteremia and lung infection compared to unvaccinatedmice, but the level of protectionwas de-
pendent on the dose of IC31.WhenPspAwas added to the trivalent protein formulation, the dose of IC31 needed to obtain protective
immunity could be reduced. These results demonstrate that a novel pneumococcal protein-based vaccine is immunogenic at an early
age ofmice and emphasize the benefits of using a combination of conserved proteins and an effective adjuvant to elicit potent protec-
tive immunity against invasive pneumococcal disease.
Streptococcus pneumoniae, or the pneumococcus, can cause life-threatening invasive diseases (meningitis and bacteremia) and
pneumonia and frequently causes otitis media in children. The
pneumococcus remains a major cause of vaccine-preventable
deaths. Current vaccines are based on capsular polysaccharides
(PSs), which are a major virulence factor and the basis for the
classification of pneumococci into more than 90 different sero-
types. Therefore, the effect of a polysaccharide-based vaccine is
restricted to the serotypes included in the vaccine, and the cover-
age varies due to different geographical serotype distributions
(13). The pneumococcal PS (PPS) vaccine contains purified PSs of
23 serotypes (PPV23) that account for 85 to 90% of invasive dis-
ease in adults in the United States. However, PSs are not immu-
nogenic in children2 years of age (8, 16, 18) and do not induce
immunological memory (26). These limitations were overcome
by conjugating pneumococcal PS to proteins, converting the PSs
from T-cell-independent (TI) to T-cell-dependent (TD) antigens
(Ags) (37) that elicit immune responses in infants and induce
immunological memory, affinity maturation, and isotype switch-
ing of antibodies (Abs). The seven-valent pneumococcal conju-
gate vaccine (PCV7), which contains 7 PPS conjugated to a non-
toxic mutant of diphtheria toxin (CRM197), is highly efficacious
against invasive disease caused by the vaccine serotypes in children
(5). Due to geographical differences in serotype distribution,
PCV7 lacks many serotypes that cause serious pneumococcal dis-
ease in developing countries (12). Also, serotype replacement in
the nasopharynx following vaccination with PCV7 has been re-
ported (44), resulting in pneumococcal diseases caused by sero-
types not included in the vaccine (14, 15, 38, 43). Ten-valent and
13-valent PCVs have recently been licensed, increasing the sero-
type coverage, but the conjugation technology is expensive, limit-
ing access to PCVs in resource-poor countries.
A new generation of protein-based pneumococcal vaccines is
being developed. Proteins are immunogenic at birth and induce
immunological memory. Well-conserved protein vaccines could
provide broad serotype and geographical coverage and be a less
expensive alternative to PCVs. Conventional vaccine develop-
ment is based on Ags with known roles in bacterial pathogenesis,
but more recent searches for vaccine candidates are based on
genomic approaches. Reverse vaccinology (35) utilizes the whole
bacterial genome sequence to predict proteins that are suitable
vaccine candidates and has proven effective for various pathogens,
in particular Neisseria meningitides serogroup B (33). The
ANTIGENome technology is another approach developed to se-
lect novel pneumococcal vaccine candidates using genomic sur-
face display libraries to identify proteins recognized by Abs in sera
from patients recovering from invasive disease as well as healthy
noncarrier adults exposed to the pathogen (24). The
ANTIGENome technology identified the majority of known pro-
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tective pneumococcal proteins, including PspA and PspC, and
further discovered two novel antigens, PcsB and StkP, that both
have almost 100%amino acid identity between different serotypes
and strains and are thus promising vaccine candidates (10). PcsB
is important for pneumococcal cell wall synthesis and survival (27,
28). It is not essential for the pneumococcus, but a PcsB deletion
causes greatly reduced growth in vitro and a complete loss of vir-
ulence (10). StkP has amino acid sequence homology to serine/
threonine kinases and was suggested previously to play a role in
cell wall synthesis, cell-cell signaling, virulence, and resistance to
stress conditions (9, 29, 32). StkP deletion mutants are less viru-
lent in mice, and electron microscopic studies revealed an altered
cell shape, indicating a defect in cell division (10).
Young infants are the prime targets for protein-based pneu-
mococcal vaccines. We therefore evaluated the immunogenicities
and protective efficacies of four pneumococcal proteins, PcsB,
StkP, PsaA, and PspA, in a neonatal mousemodel using intranasal
(i.n.) challenge with virulent pneumococci to mimic the natural
route of infection. Since infants respond weakly to vaccinations
(42), we tested the effects of two potent adjuvants, alum and IC31,
on the immune response to the pneumococcal proteins. Alum is
still the most extensively used human adjuvant and the only adju-
vant used with pneumococcal vaccines. In recent years, three
novel adjuvants, MF-59, ASO3, and ASO4, have been licensed for
human use (reviewed in reference 7). Although alum has been
shown to improve the Ab response to several Ags, including diph-
theria and tetanus toxoids, it is a poor inducer of Th1 immune
responses and may thus be suboptimal for neonates that have
Th2-dominant immune responses. Effective Th1 responses are
required to protect against several infectious diseases, including
tuberculosis (TB), HIV/AIDS, and hepatitis C. Furthermore,
Th17 responses have been shown to play an important role in
protecting mice against pneumococcal colonization (19, 20). The
total amount of alum acceptable for human vaccines (1.0 to 1.5
mg/vaccination) restrains the number of Ags that can be used
within the same formulation. IC31 is a novel two-component ad-
juvant consisting of an antibacterial peptide (KLKL5KLK [KLK])
and the synthetic oligodeoxynucleotide ODN1a that signals
through Toll-like receptor 9 (TLR9). Unlike alum, IC31 enhances
both Th1- andTh2- associated humoral responses and a high level
of production of the Th1-associated cytokine gamma interferon
(IFN-) (1, 36, 39). Results fromhuman trials of IC31 showed that
when combined with the TB vaccine candidate Ag85B-ESAT6, it
was well tolerated and highly immunogenic, with strong Th1 re-
sponses persistingmore than 2.5 years following vaccination (48).
We have previously shown that IC31 enhances themurine neona-
tal Ab response to a monovalent PCV and improves protection
against pneumonia and lung infection (31).
In this study, we demonstrate protective effects of a protein-
based pneumococcal vaccine in a neonatal murine model. How-
ever, the levels of protection depend on the combination of pro-
tein candidates and the dose of the Th1-promoting adjuvant IC31.
MATERIALS AND METHODS
Mice. Adult NMRI mice were purchased from M&B AS (Ry, Denmark)
and allowed to adapt for 1 week before matching. They were kept in
microisolator cages with free access to commercial food pellets and water
and were housed under standardized conditions with regulated daylight
humidity and temperature. Breeding cages were checked daily, and pups
were kept with their mothers until weaning at 4 weeks of age. The study
was approved by the Animal Experimental Committee of Iceland.
Vaccine and adjuvants. PcsB, StkP, PsaA, and PspA were identified
and produced by Intercell AG (Vienna, Austria) as described previously
(10). The adjuvants used were IC31, provided by Intercell, and aluminum
hydroxide gel adjuvant (Brenntag Biosector, Denmark), here called alum.
Immunization.Neonatal (7-day-old)mice (8 per group) were immu-
nized subcutaneously (s.c.) in the scapular girdle regionwith 50l of each
vaccine formulation. Sixteen days later, mice received a second dose (100
l) of the vaccine formulation, and a third dose (200l) was administered
2 weeks later. Tris buffer (10mMTris–70mMNaCl [pH 6]) was added to
the vaccine formulation to obtain the right volume. Each mouse received
20g of each protein, i.e., PcsB, StkP, PspA, andPsaA, alone or combined.
IC31 was given at three different doses: 15.75 nmol KLK and 0.63 nmol
ODN1a (IC31 lower low dose [LLD]), 50 nmol KLK and 2 nmol ODN1a
(IC31 low dose [LD]), or 90 nmol KLK and 3.6 nmol ODN1a (IC31 high
dose [HD]), as indicated in the respective figure legends. Alumwas used at
a dose of 0.48% aluminum hydroxide gel adjuvant (Brenntag Biosector,
Denmark) per 1 g of protein.
Blood samples. Three weeks after the priming and then weekly, mice
were bled from the tail vein, and serum was isolated and stored at20°C
until use.
Pneumococci and mouse challenge. Two weeks after the second im-
munization or 4 weeks after priming, mice were challenged intranasally
(i.n.) with S. pneumoniae serotype 1 (ATCC6301; American TypeCulture
Collection, Rockville, MD). A stock solution was maintained in tryptose
broth plus 20% glycerol at70°C. One day before challenge, the bacteria
were plated onto blood agar made of tryptone soya agar (Oxoid, Cam-
bridge, United Kingdom) supplemented with gentamicin and horse se-
rum (Keldur, Reykjavik, Iceland) and incubated at 37°C in 5% CO2 over-
night. Isolated colonies were transferred into Todd-Hewitt broth
(Oxoid), cultured at 37°C to log phase for 3.5 h, and resuspended in sterile
saline. Serial 10-fold dilutions were plated onto blood agar to determine
the challenge dose as CFU in 50 l. The challenge dose for each experi-
ment is given in the representative figure legends.
Twenty-four hours after i.n. challenge, themice were sacrificed, blood
samples were taken from the tail vein, and 10-fold serial dilutions were
plated onto blood agar that included Staph/Strep selective supplement
containing nalidixic acid and colistin sulfate (Oxoid) and incubated at
37°C in 5% CO2 overnight. Bacteremia was determined as the number of
CFU per ml of blood. Lungs were removed, homogenized, and diluted
into 3 ml saline, and serial dilutions were plated onto blood agar plates,
which were incubated for 48 h at 37°C under anaerobic conditions. Pneu-
mococcal lung infection was expressed as CFU per ml of lung homoge-
nate. Depending on the first dilution used, the detection limits were 2.2
log CFU/ml lung homogenate and 1.3 log CFU/ml blood.
Antibodies to PcsB, StkP, PsaA, and PspA. PcsB-, StkP-, PspA-, and
PsaA-specific Abs (IgG) were measured by an enzyme-linked immu-
nosorbent assay (ELISA). Briefly, microtiter plates (Immulon 2HB;
Thermo) were coated with 100 l/well of 1 g/ml of PcsB, StkP, PspA, or
PsaA in phosphate-buffered saline (PBS) overnight at 4°C. Serum samples
were diluted 1:50 in PBS containing 0.05% Tween 20 (Sigma, St. Louis,
MO) and 2% bovine serum albumin (BSA) (Sigma). The plates were
washed 3 times with PBS-Tween, and the serum samples were added,
serially diluted, incubated in duplicates for 2 h at room temperature (RT),
washed as described above, and incubated for 2 h at RT with horseradish
peroxidase-conjugated goat anti-mouse IgG Abs (Southern Biotechnol-
ogyAssociates Inc., Birmingham,AL) diluted 1:20,000 in PBS-Tween–2%
BSA. The plates were washed as described above, and the enzyme reaction
was developed by the addition of 3,3=,5,5=-tetramethylbenzidine peroxi-
dase substrate (Kem-En-Tec Diagnostics A/S, Taastrup, Denmark) to the
mixture. After 10 to 30 min, the reaction was stopped by the addition of
100l of 0.18MH2SO4 to eachwell. The absorbance wasmeasured at 450
nm with an ELISA spectrophotometer (Original Multiscan Ex; Thermo
Electron Corporation, Vantaa, Finland). Serial dilutions of a reference
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serum, obtained by immunizing adult mice with each of the protein an-
tigens and IC31, were included on each plate. The titer of the reference
serum corresponded to the inverse of the serum dilution giving an optical
density of 1.0. The titers of the test serum samples were calculated from
the reference serum and based on a minimum of four data points and
parallelism between the serum samples and the reference curve. The de-
tection limit was 1.0 ELISA units (EU)/ml. The results were expressed as
the median log ELISA units per ml with interquartile ranges.
Avidity. The avidity of antigen-specific IgG Abs in sera was measured
by using the ELISA protocols described above but with the addition of a
potassium thiocyanate (KSCN) elution step (11). Microtiter plates were
coated with specific Ags as described above. Serum samples were diluted
1:50 in PBS-Tween. The plates were then washed three times with PBS
containing 0.05% (vol/vol) Tween 20 (Sigma)–2%BSA, and the sera were
serially diluted and incubated in duplicates in the Ag-coated plates for 2 h
at RT. After washing 3 times with PBS-Tween, 2-fold dilutions of KSCN,
ranging form 0.117M to 7.5M, or PBS-Tween (indicating 100%binding)
were added, and incubation continued for 15 min at RT. After washing 3
times with PBS-Tween, the plates were incubated for 2 h with alkaline-
phosphatase-labeled anti-mouse IgG (Southern Biotech, Birmingham,
AL) that was diluted to a working concentration of 1:3,000 in PBS-Tween.
The reactionmixture was developed by using 5-mg tablets of phosphatase
substrate (Sigma) in substrate buffer (pH 9.8), and the absorbance was
read at 405 nm by use of a Multiscan Ex spectrophotometer. The results
were expressed as the avidity index (AI), which is defined as the M KSCN
needed to displace 50% of bound IgG antibodies.
Statistical analysis. The overall P value was calculated by using the
Kruskal-Wallis nonparametric analysis of variance (ANOVA). The nonpara-
metric Mann-Whitney rank sum test and the Fisher exact test were used for
statistical comparisons between groups. The Fisher exact test was performed
to compare the frequencies of protected mice between the groups using
CFU/ml lower than the mean CFU plus 2 the standard deviation in the
control group as a measure of protection. The program Sigma Stat was used
for statistical analysis. A P value of0.05 was considered statistically signifi-
cant.
RESULTS
Neonatal immunization with the quadrivalent protein formu-
lationand the adjuvant IC31 reducesbacteremia and lung infec-
tion. Neonatal (7-day-old) mice were immunized with a single
pneumococcal protein, PcsB, StkP, PsaA, or PspA (20 g of each
protein), with IC31 (50 nmol KLK and 2 nmol ODN1a, which
corresponds to half of the dose previously used for adult mice
[39]) or all four proteins combined (quadrivalent protein formu-
lation), with orwithout IC31.Mice receiving Tris buffer were used
as a negative control. The immunizations were repeated twice at
2-week intervals. Two weeks after the third immunization, the
mice were challenged with S. pneumoniae serotype 1 to evaluate
protection against bacteremia and lung infection.
All four single proteins were immunogenic in neonatal mice
when administered with IC31. Due to poor immune responses
early in life, the single proteins were not tested without adjuvant,
but the immune responses were compared with those elicited by
the quadrivalent formulation given with and without IC31.When
immunized with the quadrivalent protein formulation, IC31 sig-
nificantly enhanced the Ab responses to PcsB (P  0.003), StkP
(P 0.001), and PspA (P 0.001) compared to the Ab responses
to the quadrivalent formulation administered without an adju-
vant (Fig. 1). Furthermore, theAb responsewasmore rapid for the
adjuvanted formulation, and higher Ab levels were observed
against all proteins except PsaA at all time points measured, 2
weeks after the first, second, and third doses.
A significant reduction in the level ofbacteremiacompared to that
of the negative-control groupwas observed after immunizationwith
two single proteins given with IC31, StkP (P 0.05) and PspA (P
0.05) (Fig. 2A), but none of the single proteins admixed with IC31
reduced lung infection(Fig. 2B).Asignificant (P0.05) reductionof
both bacteremia and lung infection was observed only for mice re-
ceiving the quadrivalent protein formulation and IC31, whereas the
quadrivalent formulation without adjuvant reduced neither bacter-
emia nor lung infection (Fig. 2).
IC31 induces higher-level and broader Ab responses than
alum in combination with a trivalent protein formulation. The
immunogenicity and protective efficacy of a vaccine formulation
consisting of the three proteins PcsB, StkP, and PsaA (trivalent
protein formulation) in combination with alum or IC31 at differ-
ent doses (lower dose, 50 nmol KLK and 2 nmol ODN1a; higher
dose, 90 nmolKLK and 3.6 nmolODN1a)were evaluated by using
the same experimental setup as that described above. Mice receiv-
ing only alum or IC31 were used as negative controls.
Mice receiving the trivalent protein formulation without adju-
vant showed significant Ab responses to StkP (P  0.0003) and
PsaA (P 0.0002) compared with control mice that received only
adjuvant (alum/IC31), but no PcsB-specific Ab response was ob-
served (Fig. 3). Alum and either dose of IC31 significantly en-
hanced neonatal IgG Ab responses to StkP (P 0.001) and PsaA
(P 0.0002), and IC31 but not alum enhanced PcsB-specific Ab
responses (lower dose, P 0.0185; higher dose, P 0.0004) com-
pared with the trivalent protein formulation without adjuvant.
The higher dose of IC31 given with the trivalent protein formula-
tion enhanced the Ab responses to PcsB (P  0.001) and PsaA
(P  0.008) compared with alum. The higher dose of IC31 en-
hanced the StkP-specific Ab response more than the low dose of
IC31 (P 0.0052).
The adjuvant effect on the IgG subclass pattern induced by the
trivalent protein formulation was assessed. The higher dose of
IC31 enhanced PcsB-specific IgG1 titers (P  0.001) compared
with the IgG1 titers obtained with no adjuvant (Fig. 4). Alum and
the low and high doses of IC31 significantly enhanced IgG1 re-
sponses specific for StkP (P  0.001) and PsaA (P  0.010, P 
0.007, and P 0.011, respectively) compared with the responses
with the trivalent formulation without an adjuvant. The high dose
of IC31 enhanced PcsB- and StkP-specific IgG1 responses com-
pared with those induced by alum (P  0.001 and P  0.001,
respectively) or the lower dose of IC31 (P 0.001 and P 0.002,
respectively). Alum enhanced IgG2a-specific Abs for PsaA (P 
0.038) but not for PcsB or StkP compared with the trivalent pro-
tein formulation without an adjuvant. The high dose of IC31 sig-
nificantly enhanced IgG2a specific for PcsB (P  0.042) but not
for StkP or PsaA comparedwith the proteins without an adjuvant.
IgG2aAb levels specific for PsaAwere highest inmice receiving the
lower dose of IC31 and significantly higher than when alum (P
0.001) or the high dose of IC31 (P  0.008) was given with the
trivalent protein formulation.
Alum and both the lower and higher doses of IC31 significantly
enhanced the avidity of IgG Abs for StkP (P  0.002, P  0.017,
and P 0.005, respectively) and PsaA (P 0.020, P 0.006, and
P  0.006, respectively) (Fig. 5). However, the avidity of PcsB-
specific Abs was increased by IC31 at the low (P  0.0298) and
high (P 0.0006) doses but not by alum.
The level of protection elicitedby the trivalent formulation is
increased by IC31 in a dose-dependent manner, and PspA fur-
ther improves protective efficacy. The effects of increasing doses
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of IC31 on neonatal Ab responses to four proteins and protective
capacity were evaluated. A clear dose-dependent effect on protec-
tion was observed.
The trivalent protein formulation (PcsB, StkP, and PsaA) given
with the lower dose of IC31 significantly increased the frequency
of mice protected against bacteremia (P  0.026) but not lung
infection (Fig. 6). The level of bacteremia (CFU/ml) did not differ
significantly between the groups due to high variability in CFU/ml
within the immunized groups. However, when PspAwas added to
the trivalent protein formulation and given with the lower IC31
dose, a reduction in levels of both blood and lung infection was
observed (Fig. 2). Preliminary data suggest that PspA also adds to
the protection against lung infection provided by the trivalent
protein vaccine when administered with the higher dose of IC31
(see Fig. S1 in the supplemental material). A higher IC31 dose (up
to 90 nmol KLK and 3.6 nmol ODN1a) was needed for the triva-
lent protein formulation to induce a significant increase in the
number of mice protected against both bacteremia (P  0.029)
and lung infection (P 0.029) compared to the number of mice
protected with adjuvant only (Fig. 6). Mice that received the tri-
valent protein formulation alone or with alumwere not protected
against pneumococcal infections (Fig. 6). Neither single proteins
nor the quadrivalent protein formulation with a further reduced
dose of IC31 (LLD, 15.75 nmol KLK and 0.63 nmol ODN1a) elic-
ited protection against bacteremia or pneumonia (see Fig. S2 in
the supplemental material).
DISCUSSION
Protein-based pneumococcal vaccines should include conserved
pneumococcal proteins that are able to provide serotype-
independent, cost-effective protection at an early age. The selec-
tion of well-conserved proteins that play important roles in bac-
terial survival and growth reduces the risk of negative selection
caused by vaccination. Two of the newly described proteins eval-
uated in this study, PcsB and StkP, fulfill these criteria. They are
exceptionally well conserved (99.5%), and knockout strains
showed reduced growth and virulence (10). PsaA is also a highly
conserved lipoprotein produced by all pneumococci (34),
whereas PspA can be grouped into three families, but significant
cross-protection between families has been observed (22, 45).
We have demonstrated that all four proteins tested, PcsB, StkP,
PsaA, and PspA, were immunogenic in neonatal mice, provided
protection against bacteremia, and significantly reduced lung in-
fection when combined and given with the adjuvant IC31. Fur-
FIG 1 IgG antibody responses to PcsB, StkP, PspA, and PsaA are enhanced by IC31. Shown are data for PcsB (A)-, StkP (B)-, PsaA (C)-, and PspA (D)-specific
Ab responses elicited by immunizations with each protein alone or in a quadrivalent protein formulation with or without IC31 (LD, 50 nmol KLK and 2 nmol
ODN1a). IgG levels were measured by ELISA 2 weeks after one (week 2), two (week 4), and three (week 6) immunizations. The results for one experiment are
shown (n 8/group). Bars are shown asmedians of each groupwith interquartile ranges. An asterisk indicates statistically higherAb levels than those in the group
receiving Tris buffer (P  0.05). P values are shown for comparison between the groups receiving the 4 proteins with and without IC31, when statistically
significant. The overall P values, calculated by using the Kruskal-Wallis test, were a P value of 0.0006 (week 2) and a P value of 0.0001 (weeks 4 and 6) for
PcsB-specific Abs; a P value of0.001 (weeks 2, 4, and 6) for StkP-specific Abs; a P value of 0.0381 (week 2), a P value of 0.0031 (week 4), and a P value of 0.0004
(week 6) for PsaA-specific Abs; and a P value of 0.0003 (week 2), a P value of0.0001 (week 4), and a P value of 0.0002 (week 6) for PspA-specific Abs.
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thermore, two of the proteins, StkP and PspA, reduced bacteremia
when given as single proteins with IC31. PspA is one of the most
studied protein vaccine candidates and has been shown to reduce
carriage (2, 49) and protect against lethal infection (23, 49, 50) in
adult mice.More recently, a Salmonella-vectored vaccine express-
ing PspAwas shown to be immunogenic in neonatal mice, but the
level of protectionwas lower than that in adultmice (41). StkP and
PcsBhave been shown to reduce the bacterial load in lungs of adult
mice following i.n. challenge with serotypes 3 and 19F, with StkP
providing protection against serotype 19F comparable to that of
PCV7 (10). However, PcsB but not StkP protected adult mice
against death following i.n. challenge with serotype 1 (ATCC
6301, the same strain used in our study). Thus, despite using the
same challenge route and pneumococcal strain, the different re-
sults may be explained by age-dependent immune responses and
different endpoints, i.e., pneumococcal load in lung and blood in
our neonatal experiment versus the survival of adult mice in the
study byGiefing et al. (10). In our study, the pneumococcal load in
lungs was significantly reduced when a quadrivalent protein for-
mulation was given with IC31, demonstrating the benefits of elic-
iting Abs against several virulence factors of the pneumococcus.
Other research groups have shown that a combination of different
proteins increases the protective efficacy of a pneumococcal
protein-based vaccine. Thus, a double or a triple combination of
PspA, PcsB, and PspC was shown previously to provide enhanced
protection compared to that provided by each single protein alone
(6, 30). Furthermore, when using proteins that exhibit strain-
specific sequence variation, such as PspA, a combination of several
different proteinswillmore likely protect against awider variety of
strains than any single protein.
Since IC31 had proven potent in our neonatal model when
given with a PCV (31), we compared its effect in comparison to
that of alum on the neonatal Ab response to pneumococcal pro-
teins. The trivalent vaccine formulation including StkP, PcsB, and
PsaA combined with alum was thus compared to the formulation
with IC31. Both alumand IC31 enhanced theAb responses to StkP
and PsaA, but only IC31 enhanced the response to PcsB.Measure-
ments of the IgG1 and IgG2a titers and the avidity of the Abs
further revealed that IC31 induced broader IgG1 and IgG2 re-
sponses to all three proteins with increased avidity, whereas the
effects of alumwere observed only for the Ab response to StkP and
PsaA. IgG2a has been strongly correlated with opsonophagocyto-
FIG 2 A quadrivalent protein formulation admixed with a lower dose of IC31
(LD) protects neonatally immunized mice from both bacteremia and lung
infections, whereas StkP and PspA as single proteins admixed with the IC31
LD reduce only bacteremia. Pneumococcal CFU/ml in blood (A) and lungs (B)
24 h after challenge with S. pneumoniae serotype 1 is shown for each mouse,
and the median for each group (n 8/group) is indicated by a line. The IC31
LD consisted of 50 nmol KLK and 2 nmol ODN1a. The pneumococcal chal-
lenge dose was 1.18  107 CFU/mouse. P values are shown for comparison
between the immunized groups and the control group receiving Tris buffer
when statistically significant. The results are shown for one experiment (n 
8/group). The overallP value for CFU in bloodwas 0.0009, and that for CFU in
lungs was 0.0098. Further statistics are reported in Table S1 in the supplemen-
tal material.
FIG 3 IC31 induces higher and more rapid Ab responses to all three proteins
in the trivalent formulation, whereas Alum enhances only StkP- and PsaA-
specific Abs. Shown are the median IgG Ab levels specific for PcsB (A), StkP
(B), and PsaA (C) 2, 4, and 6 weeks after the first neonatal immunization at 7
days of age. The IC31 LD consisted of 50 nmol KLK and 2 nmol ODN1a, and
the IC31 HD consisted of 90 nmol KLK and 3.6 nmol ODN1a. The results for
one of two comparable experiments are shown (n 8mice/group). The over-
all P values were a P value of 0.0676 (week 2) and a P value of0.0001 (weeks
4 and 6) for PcsB-specific Abs, a P value of 0.0001 (weeks 2, 4, and 6) for
StkP-specific Abs, and a P value of 0.0001 (weeks 2, 4, and 6) for PsaA-
specific Abs.
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sis of pneumococci in the mouse (17), which is considered one of
the main host defenses against pneumococcal infections. Both
alum and IC31 induced IgG2aAbs but to different proteins. Over-
all, IC31 induced a higher level of protection against both bac-
teremia and lung infection than alum. Therefore, we concluded
that the superior protective efficacy of the trivalent protein vac-
cine with IC31 compared to that with alum can be explained by a
combination of higher levels of both the complement-fixing
IgG2a and the Fc-binding IgG1 subclasses with an increased avid-
ity of all protein-specific Abs. Although there was not a significant
correlation between protein-specific Ab levels and CFU in lungs
or blood, there was a tendency for mice with the highest pneumo-
coccal loads to have Ab levels in the lower range, whereas themice
that were totally protected had Ab levels in the higher range of
their respective groups. The lack of a correlation between infec-
tion and Ab titers for individual antigens indicates that the pro-
tective capacity of the protein vaccine is truly mediated by the
combined effects of the protein-specific Abs, Ab subclasses, and
avidity.
The protective immunity provided by IC31 combined with the
trivalent protein formulation was clearly dose dependent. Only
partial protection (only against bacteremia) was observed when
the lower dose of IC31 was given, which corresponded to half of
the adult mouse dose previously used. However, protection
against both bacteremia and lung infectionwas observedwhen the
higher dose (corresponding to a full adult dose) was given. No
protection was observed when IC31 was reduced to 15.75 nmol
KLK and 0.63 nmolODN1a (approximately one-sixth of the adult
dose). This is in contrast to our results for neonatal immunization
with PCV, where the lowest dose (15.75 nmol KLK and 0.63 nmol
ODN1a) of IC31 resulted in protection levels similar to those
foundwhen the highest dose (90 nmolKLKand 3.6 nmolODN1a)
was used in combination with proteins, with the latter inducing
even higher vaccine-specific Ab levels (31). This finding suggests
that higher levels of protein-specific Abs than PPS-specific Abs
may be required to provide full protection against pneumococcal
disease, possibly due to less exposure of the proteins on the bac-
terial surface than the PPS. Therefore, a higher dose of an effective
adjuvant might be needed with the protein vaccine than with
PCV. Two (31) and three (data not shown) doses of PCV with
IC31 resulted in complete protection in our neonatal infection
model, indicating the superior protective efficacy of the already
licensed vaccine compared to the experimental protein vaccine, at
least in this model. However, a direct comparison of the most
promising protein vaccine combination with IC31 and PCV re-
mains to be done, and the evaluation of these two vaccines upon
colonization is an interesting future task.
Interestingly, reductions in both bacteremia and lung infection
were observed when PspA was added to the trivalent protein for-
mulation given with the lower dose of IC31. Thus, in the neonatal
FIG 4 IC31 enhances the levels of both IgG1 and IgG2a Abs to the three
proteins in the trivalent vaccinemore than alum. Shown are levels of IgG1 and
IgG2a specific for PcsB (A), StkP (B), and PsaA (C) 2 weeks after the third
immunization of neonatal mice with the trivalent protein formulation with
high- or low-dose IC31, alum, or no adjuvant. The IC31 LD consisted of 50
nmol KLK and 2 nmol ODN1a, and the IC31 HD consisted of 90 nmol KLK
and 3.6 nmol ODN1a. Bars represent the medians of each group with inter-
quartile ranges. , P 0.05; , P 0.001 (compared to the group receiving
alum/IC31). The results for one of two comparable experiments are shown.
The overall P values were a P value of0.0001 (IgG1) and a P value of 0.0134
(IgG2a) for PcsB-specific Abs, a P value of 0.0001 (IgG1) and a P value of
0.0024 (IgG2a) for StkP-specific Abs, and a P value of 0.0001 (IgG1 and
IgG2a) for PsaA-specific Abs.
FIG5 Affinitymaturation is enhanced by IC31more than by alum. Shown are
avidity indexes of IgG Abs specific for PcsB, StkP, and PsaA following three
immunizations of neonatal mice with the trivalent protein formulation ad-
mixed with alum, a low or a high dose of IC31, or no adjuvant. The IC31 LD
consists of 50 nmol KLK and 2 nmol ODN1a, and the IC31 HD consists of 90
nmol KLK and 3.6 nmol ODN1a. Results for one of two comparable experi-
ments are shown. , P 0.05; , P 0.001 (compared to the group receiving
the three proteins without an adjuvant). The overall P values were a P value of
0.0002 for PcsB-specificAbs, aP value of0.0001M for StkP-specificAbs, and
a P value of0.0001 for PsaA-specific Abs.
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mouse model, the highest dose of IC31 seems to be needed for the
trivalent protein formulation to elicit protective immunity, but
the IC31 dose can be reduced if PspA is added as the fourth pro-
tein. It should be noted that the infection dose was higher in the
experiment evaluating the trivalent formula (Fig. 6) thanwhen the
quadrivalent vaccine was administered with the lower dose of
IC31 (Fig. 2), which could overestimate the additional protection
provided by PspA. However, our preliminary results demon-
strated that PspA further added to the protection against lung
infection provided by the high dose of IC31 when these two vac-
cinated groups were compared in the same experiments and thus
challenged with same pneumococcal doses.
Pneumococcal proteins may induce T-cell responses, and
CD4 Th17 cells have been shown to reduce pneumococcal colo-
nization in mice in an Ab-independent way (3, 19–21, 46, 47).
Furthermore, interleukin-17A (IL-17A) was the cytokine most
frequently secreted by human peripheral bloodmononuclear cells
(PBMCs) upon in vitro stimulation with any of the three proteins
PcsB, StkP, and PsaA (40).We have shown that the immunization
of neonatal mice with an influenza virus vaccine (Agrippal) and
IC31 elicits high-level IFN- and IL-17 responses, indicating that
IC31 is a potent Th1- and Th17-evoking adjuvant (T. A. Olafsdot-
tir et al., unpublished data). It is therefore conceivable that the
pneumococcal protein vaccine combined with IC31 could also
contribute to protection against pneumococcal colonization.
However, the ability of protein Ags to induce IL-17 upon coloni-
zation has been shown to be the best indication of whether the
proteins can protect against colonization in mice. Many proteins
eliciting a Th17 response to colonization donot necessarily induce
protectiveAbs against pneumococcal diseases (25). The protective
capacity of the three-valent (PcsB, StkP, and PsaA) protein vac-
cine against colonization awaits further evaluation.
The ANTIGENome technology that identified and selected the
two pneumococcal protein candidates PcsB and StkP is based on
their capacity to induce natural immune responses in humans
during exposure to or infection by the pneumococcus (10). PcsB
and StkP are furthermore exceptionally well conserved. The re-
sults from our studies with neonatal mice support their potential
for use in a protein-based vaccine for the youngest age group.
However, the coadministration of an effective adjuvant that in-
duces high levels of both complement-fixing and Fc-binding Abs
of high avidity to all protein candidates in a vaccine is essential for
protective efficacy, at least in themurinemodel. The translation of
the murine data to humans is complicated by the fact that the
human complement-fixing IgG1 and IgG3 subclasses (4) are not
as directly associated with a Th1 response in humans as the IgG2a
subclass is in themouse. Still, murinemodels are the first choice to
evaluate the protective efficacy of novel vaccine candidates. There-
fore, a careful selection of an adjuvant enhancing mixed Ab sub-
classes as well as the avidity to all Ags is necessary to fully evaluate
their protective potential. Furthermore, novel vaccine candidates
should be evaluated in neonatal and infant models that exhibit
limitations in the immune systemcomparable to those of themain
human target group.
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